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Toll-like receptor 9 
A B S T R A C T   
Introduction: Circulating DNA can be pro-inflammatory when detected by leukocytes via toll-like receptor 9 
(TLR9). Cell-free fetal DNA (cff-DNA) of placental origin, circulates in pregnancy, and increased concentrations 
are seen in conditions associated with placental and maternal inflammation such as pre-eclampsia. However, 
whether cff-DNA is directly pro-inflammatory in pregnant women and what regulates cff-DNA levels in preg-
nancy are unknown. 
Methods: Using a human term placental explant model, we examined whether induction of placental inflam-
mation can promote cff-DNA release, and the capacity of this cff-DNA to stimulate peripheral blood mononuclear 
cells (PBMCs) from pregnant women. 
Results: We demonstrate lipopolysaccharide (LPS)-mediated inflammation in placental explants and induced 
apoptosis after 24 h. However, this did not increase levels of cff-DNA generation compared to controls. 
Furthermore, the methylation status of the cff-DNA, was not altered by LPS-induced inflammation. Cff-DNA did 
not elicit production of inflammatory cytokines from PBMCs, in contrast to exposure to LPS or the TLR9 agonist 
CpG-ODN. Finally, we demonstrate that cff-DNA acquired directly from pregnant women did not differ in 
methylation status from placental extracted DNA, or from placental explant generated cell-free DNA, and that, 
unlike Escherichia coli DNA, this cff-DNA has a low level of unmethylated CpG sequences. 
Discussion: Our data suggest that placental inflammation does not increase release of cff-DNA and that placental 
cff-DNA is not pro-inflammatory to circulating PBMCs. It thus seems unlikely that high levels of cff-DNA are 
either a direct consequence or cause of inflammation observed in obstetric complications.   
1. Introduction 
Cell-free fetal DNA (cff-DNA) is found in the maternal circulation as 
early as 5 weeks of gestation [1,2]. It is predominantly of placental 
origin and is generated during cell-death, likely by apoptosis of the 
trophoblasts in the syncytiotrophoblast layer [2–5]. Although the 
method of release is not completely clear, there is a strong association 
between cff-DNA and placental microparticles including exosomes. 
Multiple studies have found that placental microparticles can release 
cff-DNA and have demonstrated the presence of fetal DNA in, or bound 
to, placental microparticles [6,7]. The levels of circulating cff-DNA in-
crease throughout gestation [8,9]. Interestingly, women who develop 
obstetric pathologies that are related to placental inflammation, such as 
pre-eclampsia and preterm labour, have higher levels of cff-DNA 
compared to uncomplicated pregnancies [3,10–15]. Despite extensive 
research, the pathophysiology of these obstetric complications are not 
completely understood, resulting in an unmet need for effective treat-
ments [16,17]. However, it is well established that inflammation plays a 
key role in preterm labour [18,19] and pre-eclampsia [14,17] and 
indeed there is some evidence that they share pathophysiological 
mechanisms [20,21]. 
cff-DNA can be discriminated from maternal cell-free DNA by iden-
tifying fetal DNA specific characteristics such as sex (if a male fetus is 
present) or various genes that are differentially methylated in the 
placenta [22]. Studies have indicated that cff-DNA may be less meth-
ylated overall than adult DNA [21,23]. Because the innate pattern 
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recognition receptor Toll Like Receptor 9 (TLR9) is activated by 
unmethylated CpG oligonucleotide (ODN) sequences [24], cff-DNA may 
have the potential be a TLR9 ligand and thereby potentially be 
pro-inflammatory. cff-DNA has therefore been hypothesized to play a 
role in the pathophysiology of preterm labour and pre-eclampsia [11,13, 
14,23,25]. 
In a model of miscarriage in preterm birth, human fetal DNA caused 
TLR9-dependent fetal resorption in mice [21]. In a model of 
pre-eclampsia, injection of CpG-DNA, caused vascular inflammation, 
resulting in maternal hypertension and vasoconstriction in rats [26]. 
Furthermore, cell-free DNA of tumor origin can elicit an inflammatory 
response in epithelial cells through TLR9 [27,28]. Importantly, maternal 
circulatory cytokines produced upon TLR9 activation, such as IL-6, and 
chemokines, such as CXCL10, have been associated with obstetric 
complications, including pre-eclampsia and preterm birth [29–31]. 
However, it is unknown whether cff-DNA contributes to the inflamma-
tion seen in these pathologies, and whether this can be a directly 
pro-inflammatory stimulus for circulating leukocytes from pregnant 
women. 
The mechanisms by which cff-DNA is released and why circulating 
levels of cff-DNA are higher in women who develop certain pregnancy 
complications remains elusive. In vitro studies have demonstrated that 
inflammation, induced by lipopolysaccharide (LPS), can increase pro-
grammed cell-death (apoptosis) in placental explants [32], and can in-
crease cff-DNA release from murine placental explants [33]. We 
hypothesized that in utero inflammation would promote apoptosis and 
increase cff-DNA release from the placenta into the circulation resulting 
in an increase of cff-DNA, inducing systemic leucocyte-mediated 
inflammation, contributing to disease the pathogenesis in women with 
pre-eclampsia and/or preterm birth. 
In this study, we examine the effect of LPS-mediated inflammation 
on cff-DNA release in a primary human placental explant model, and 
investigate the pro-inflammatory effects of cff-DNA on maternal pe-
ripheral blood mononuclear cells. 
2. Materials and methods 
2.1. Human samples 
Placental tissues and whole blood (up to 30 ml) from pregnant 
women (N ¼ 31) were collected as part of Edinburgh Reproductive 
Tissue Bio Bank (NHS Research ethics committee approval reference 13/ 
ES/0126). Samples were donated by women with term pregnancies 
(37–40 weeks gestation) who were not in labour, had a BMI < 30, with 
no pregnancy complications, no blood borne diseases, no immunosup-
pressive disease or medication, and no current signs of infection. 
2.2. Placental explant culture and stimulation 
Within 30 min of delivery, 10 � 10 cm of placental tissue with no 
visible areas of calcification or hemorrhage was dissected and immedi-
ately immersed cold Dulbecco’s phosphate-buffered saline (DPBS; 
Gibco). 1 � 1 cm pieces were dissected and snap frozen for use as sample 
controls (see below). Two washes were performed with DPBS, followed 
by a wash in culture medium (RPMI (Gibco) containing 10% Fetal 
Bovine Serum, 1% penicillin/streptomycin). While immersed in culture 
medium, placental pieces of approximately 150 mg were separated, 
using forceps and knife, into separate 6-well plates (one villous explant 
of 150 mg per well) and then cultured at 37 �C, ~18% PO2, 5% CO2. 
These placental explants were then stimulated with LPS (derived from 
E. coli 0111:B4 Sigma) at 2 ng/ml, 20 ng/ml or 200 ng/ml for 1, 6 or 24 
h. Placental samples were stimulated with LPS in triplicate. Superna-
tants were collected for cff-DNA extraction and quantification and ex-
plants were snap frozen for further analysis. 
2.3. Quantification of Caspase 3 and 7 in placental explants 
Placental explants and placental sample controls were lysed with 
350 μl luciferase cell lysis buffer (Promega E1531) using the Qiagen 
tissuelyser for 2 � 2 min at 250 Hz. Protein concentration was used for 
normalization between samples and was quantified using the Bio-rad 
protein quantification assay. All samples were eluted with cell lysis 
buffer to 1 mg/ml of protein. 50 μl of Caspase 3/7 Glo buffer (Promega 
G8090) was added to 50 μl of sample and incubated for 90 min in a clear 
96-well plate. Samples were analysed in duplicate. Results were read at 
490 nm in luminescence plate reader and quantified relative to sample 
controls. Results under zero were regarded as non-detected. 
2.4. Cell-free fetal DNA extraction and quantification 
Supernatant was harvested from placental explant cultures and cff- 
DNA extracted using the QIAamp Circulating Nucleic Acid Kit (Qia-
gen). Clinical cff-DNA was harvested in the same manner from plasma 
recovered from freshly drawn blood (less than hour after venepuncture) 
from EDTA (Sarstedt) tubes. The manufacturer’s protocol was followed, 
using 1 μg carrier RNA and eluting in buffer AE (10 mM Tris-Cl, 0.5 mM 
EDTA; pH 9.0). Quantification of the cff-DNA isolated was performed 
with an absolute quantitation Real-Time multiplex PCR machine (ACB/ 
SRY), over seven serial dilutions, using a standard curve of placental 
DNA. cff-DNA was quantified in pg/μl per mg of villous tissue in each 
placental explant culture. Clinical cff-DNA for methylation quantifica-
tion was quantified using Nanodrop spectrometry. 
2.5. Placental and adult DNA extraction 
Human placental DNA was extracted from placental tissue, which 
had been snap frozen at time of collection, using the Qiagen Blood & 
Tissue DNA extraction kit with prolonged lysing period for increased 
fragmentation (2 � 2 min at 25 Hz). This DNA was used as a control for 
cff-DNA validation and quantification, and as a control stimulus in 
parallel to cff-DNA in in vitro cell stimulation experiments. Adult DNA 
was extracted from whole blood from a healthy non-pregnant woman 
(ERTBB 13/ES/0126) in sodium citrate tubes. The kit described above 
was used following manufactures protocol for whole blood DNA 
extraction. Adult DNA and placental DNA were quantified using Nano- 
spectrometry. 
2.6. Peripheral blood mononuclear cells (PBMC) isolation and 
stimulation 
Whole blood was acquired as part of Edinburgh Reproductive Tissue 
Bio Bank (NHS Research ethics committee approval reference 13/ES/ 
0126) in sodium citrate tubes. PBMCs were harvested using Histopaque 
with a density gradient of 1.07 g/ml, washed twice with PBS, and finally 
washed with the culture medium (RPMI with 10% FCS and 5% Peni-
cillin/Streptomycin). Cell number and viability was assessed using a 
haemocytometer and Trypan blue staining. PBMCs were plated at 2.0 �
106/ml in 12-well plates and maintained at 37 �C, 5% CO2 for 3 h, before 
stimulation with 1 μg/ml CpG oligodeoxynucleotides 2395 (ODN; 
Invivogen) [34], 1 μg/ml E. coli DNA (dsDNA E. coli Invivogen), 0.5 
μg/ml cff-DNA, or vehicle (endotoxin-free LAL-water; Invivogen). Su-
pernatants were collected after 18 h culture at 37 �C, 5% CO2. 
2.7. Enzyme-linked immunosorbent assay (ELISA) 
R&D Duoset ELISAs for IL-6, IL-8, TNF-α, CXCL-10 were used for 
cytokine analysis, according to the manufacturer’s protocols. Superna-
tants from PBMC stimulation studies were used after being centrifuged 
for 1 min at 9391�g to spin down any residual cell debris. 
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2.8. Methylation quantification 
Whole DNA methylation quantification was performed using Epi-
gentek MethylFlash Global DNA Methylation (5-mC) ELISA Easy Kit 
(Colorimetric). The manufacturer’s protocol was followed. Whole DNA 
was methylated using M.SssI methyltransferase (New England BioLabs), 
using manufacturer’s protocol, with methylation halted by incubation at 
65 �C for 20 min. This yielded the maximum amount of methylated 
CpGs. The level of unmethylated CpGs in starting materials was quan-
tified by subtracting the amount of methylation quantified after use of 
methylation enzyme (maximum methylation) to the amount of 
methylation quantified without use of the methylation enzyme. 
2.9. Statistics 
Data in graphs are show as mean � standard deviation (SD). In vitro 
stimulations were analysed using one-way or two-way ANOVA with 
Dunnet’s or Tukey’s multiple analysis post-test. Statistical analyses were 
performed with GraphPad Prism version 7.0 (GraphPad, San Diego, CA). 
p < 0.05 was considered statistically significant. 
3. Results 
3.1. LPS induced inflammation and apoptosis in placental explants 
Placental explants, cultured with 2, 20 or 200 ng/ml of LPS or vehicle 
for 1, 6 or 24 h, showed a significant and concentration-dependent in-
duction of TNF-α release, demonstrating LPS-induced inflammation 
(Fig. 1A). 
To determine the effect of LPS-induced inflammation on cell death, 
the induction of apoptosis was evaluated by measuring caspase 3/7 
activation in the inflamed placental explants (treated with 200 ng/ml 
LPS for 6 or 24 h) relative to vehicle-treated control samples (N ¼ 3, 
Fig. 1B). A significant increase in caspase 3/7 activation was seen in the 
LPS-treated placental explants at 24 h. These data demonstrate that LPS- 
mediated inflammation induced apoptosis by 24 h (Fig. 1B). 
3.2. LPS-induced inflammation and cell death does not increase cff-DNA 
production by placental explants 
Unstimulated placental explants showed a significant increase in cff- 
DNA release at 24 h, compared to the 1-h samples (N ¼ 3), but this was 
observed to be irrespective of LPS stimulation (Fig. 2). In order to more 
closely evaluate the effect of LPS at a time point prior to high sponta-
neous cff-DNA generation, concentration response experiments were 
repeated at 6-h (N ¼ 6, Fig. 2). No significant cff-DNA release was seen at 
any of the concentrations of LPS used at 6 h, despite the pro- 
inflammatory cytokine response. 
Therefore, the cff-DNA generated in this model was produced inde-
pendent of LPS-induced apoptosis. 
3.3. Placental explant cff-DNA does not induce inflammation in human 
PBMCs from pregnant women 
To assess the capacity of primary human placental explant cff-DNA 
to elicit an inflammatory response, PBMCs isolated from pregnant do-
nors were cultured for 18 h in the presence of 500 ng/ml cff-DNA, 
generated ex-vivo from unstimulated cultured placental explants after 
24 h of culture. Dosages above 500 ng/ml were not used because this 
would be not physiological in maternal blood [35], a dose response was 
performed for 5 ng/ml, 50 ng/ml and 500 ng/ml, where lower dosages 
did not produce an inflammatory response. TLR9-agonist CpG ODN 
(ODN; 1 μg/ml), E. coli DNA (1 μg/ml) or LPS (500 ng/ml) were used as 
positive controls. PBMCs stimulated with cff-DNA showed no difference 
in the levels of IL-6, CXCL10, TNF-α, or IL-8 produced, compared to 
vehicle-treated controls. In contrast, PBMCs stimulated with LPS showed 
a significant increase in IL-6, TNF-α and IL-8 production and ODN 
induced significant CXCL10 production (Fig. 3). This demonstrates that 
primary human placental explant cff-DNA does not induce an inflam-
matory response in PBMCs from pregnant women. 
3.4. Primary human placental explant cff-DNA is not hypomethylated 
In order to determine the methylation status of the cff-DNA gener-
ated by our model, we quantified the proportion of CpG islands that 
were hypomethylated on the primary human placental explant cff-DNA, 
when compared to placental genomic DNA, adult human genomic DNA, 
clinically acquired cff-DNA (from three pregnant women between 39 
and 40 weeks of gestation), and E. coli DNA (Fig. 4). This was calculated 
by quantifying total methylation of CpG sequences in the DNA samples 
after use of the M.SssI methylation enzyme, and subtracting total 
amount of pre-exisiting methylation quantified in the untreated sample. 
These analyses demonstrated that ~8% of the CpG motifs on E. coli DNA 
(a known TLR9 ligand) were unmethylated at baseline. In contrast, there 
was no evidence that cff-DNA (both from placental explant origin and 
pooled from the plasma of three pregnant women), or placental or adult 
genomic DNA, was significantly differentially methylated before or after 
treatment with M.SssI methylation enzyme. Thus, no evidence of 
hypomethylation was found on cff-DNA, making it unlikely to be an 
effective TLR9 agonst. These data are therefore compatible with our 
experiments demonstrating that cff-DNA is not proinflammatory. 
Furthermore, we demonstrate that cff-DNA acquired from LPS-exposed 
placental explants did not have ay significant alteration to the methyl-
ation composition. These data confirm that E. coli DNA is heavily 
unmethylated compared to human DNA, but failed to show cff-DNA 
being hypomethylated when compared to adult genomic DNA. 
Fig. 1. LPS exposure induces inflammation and apoptosis in human placental explants. Placental explants were stimulated with different dosages of LPS. (A) 
TNF- α production increased in a concentration-dependent manner after 6 and 24 h (N ¼ 3) exposure to LPS. ND ¼ Not detected. Two-way ANOVA, Tukey’s multiple 
comparisons test (B) Caspase 3/7 activity from placental explants (N ¼ 3) is significantly increased after 24 h of 200 ng/ml LPS stimulation, two-way ANOVA, 
Tukey’s multiple comparisons test. All bars represent mean with �SD, * ¼ p � 0.05; ** ¼ p � 0.01, *** ¼ p � 0.001, **** ¼ p � 0.0001. 
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4. Discussion 
This study demonstrates that, in a primary human placental explant 
model; placental inflammation does not increase cff-DNA production, 
nor alter the methylation composition of cff-DNA, and that cff-DNA from 
human placental origin does not elicit a pro-inflammatory response from 
PBMCs from pregnant women. These findings suggest that placental- 
derived cff-DNA alone is not pro-inflammatory and that placental 
Fig. 2. LPS-induced inflammation and cell 
death does not increase cff-DNA production in 
human placental explants. Placental explants 
were stimulated with various doses of LPS and su-
pernatant was harvested for cff-DNA quantifica-
tion. cff-DNA production (measured by quantifying 
the SRY gene) significantly increased at 24 h, 
irrespective of LPS stimulation, compared to 1 h 
non-stimulated samples, two-way ANOVA, Tukey’s 
multiple comparisons test (N ¼ 3 at 1/24 h and N 
¼ 6 at 6 h). NS ¼ no stimulation. One-way ANOVA. 
Bars represent mean with �SD, * ¼ p � 0.05; ** ¼
p � 0.01, *** ¼ p � 0.001, **** ¼ p � 0.0001.   
Fig. 3. Human placental explant cff-DNA does not induce inflammatory responses in PBMCs from pregnant women. PBMCs from pregnant women were 
exposed to placental explant cff-DNA (500 ng/ml), CpG ODN (ODN; 1 μg/ml), E. coli DNA (1 μg/ml) or LPS (500 ng/ml) for 18 h before determination of cellular 
responses by ELISA assessment of supernatant. Sample size between 3 and 14, variable for different chemokines and stimulations. Data represent means � SD. One- 
way ANOVA with Dunnett’s multiple comparison test was performed for all cytokines and chemokines; **, p � 0.01, ***, p � 0.001, ****, p � 0.0001 compared 
to vehicle. 
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inflammation is unlikely to account for the increase in cff-DNA seen in 
obstetric complications associated with placental inflammation such as 
pre-eclampsia and preterm birth. 
To our knowledge, this is the first study to use placental-derived cff- 
DNA generated from primary human placental explants as a stimulant 
on PBMCs from pregnant women. cff-DNA from term placentae were 
chosen, as mouse term placental DNA has been previously described to 
have the shortest telomere lengths compared to earlier in gestation [23] 
and telomere fragments have shown to affect the ability of DNA to elicit 
inflammation [23]. The cff-DNA used in our studies was released by 
placental explants and extracted using a specific cell-free DNA extrac-
tion kit. It was therefore proposed to be comparable to cff-DNA observed 
in systemic circulation during pregnancy [8,36]. The methylation pro-
file of this placental explant cff-DNA was found to be comparable to 
cff-DNA collected directly from the blood of pregnant women. However 
samples had to be pooled from three different pregnant women to enable 
this analysis, and the yield was too low to enable testing of the inflam-
matory potential of cff-DNA from pregnant women in parallel with 
placental explant cffDNA; a limitation of our study. New techniques 
increasing the recovery of cff-DNA are being developed, and thus future 
studies may be able to use clinical cff-DNA in their experiments [37]. 
We examined the effects of LPS on inflammation, apoptosis and cff- 
DNA production using a placental explant culture. LPS was chosen as 
this is known to be a potent inducer of inflammation in placental ex-
plants by causing an increase in IL-6, IL-1β, IL-1α and TNF-α in term 
placental explants [38]. In placental explants, LPS has shown to cause a 
proliferation in placental resident macrophages, also known as Hofbauer 
cells [38], that can elicit a potent inflammatory response [39]. LPS has 
been used in various in vivo models for eliciting preterm birth [40,41] 
and recently, the experimental benefit of LPS in pre-eclampsia models 
has been emphasized, where LPS caused a pre-eclampsia-like phenotype 
in rats [42]. However, other clinically relevant inducers of inflammation 
and their effect on cff-DNA release, including bacteria or uric acid 
should be explored in future studies. 
LPS-induced apoptosis was seen by an increase in caspase 3/7 ac-
tivity. However, this method is limited due to the inability to demon-
strate where apoptosis was taking place. cff-DNA is released primarily 
from the synctiotrophoblast layer of the placenta [2], and our methods 
cannot demonstrate the presence or absence of apoptosis in this site. 
This might explain partly, despite seeing general inflammation-induced 
apoptosis, we did not see an increase in cff-DNA release. 
These experiments were limited to three individual placental sam-
ples as this sample size was sufficient to show a statistically significant 
increase in inflammation and apoptosis. However, no effect was seen on 
cff-DNA production. A subsequent power analysis demonstrated that 32 
cases would be needed to demonstrate a difference between untreated 
placental explants and LPS treated explants, however, this number was 
not feasible to obtain in this study. Atmospheric oxygen was used for the 
placental explant culture, however, future studies should allow for 
adjusted oxygen levels as recent studies have shown that these levels of 
oxygen can favour pro-inflammatory and apoptotic transcriptomic re-
sponses [43]. In our study, all three samples were from women who gave 
birth to male babies, as this would ensure the ability to quantify cff-DNA 
by using the clinically established method of quantifying cff-DNA 
through qRT-PCR quantification of the SRY-gene. However, studies 
have demonstrated the LPS exposure to placental trophoblasts may have 
a sexually dismorphic effect [44], and this should be taken into account 
when interpreting these results. Finally, work using placental explant 
culture models has its limitations, as it is an ex vivo model, and future 
work should consider experiments using placental organoids, which is a 
promising model for future obstetric experimental work [45]. 
Our findings conflict with findings from Scharfe and colleagues who 
found that human genomic fetal DNA caused increased IL-6 production 
in PBMCs from pregnant women [21]. The different type of DNA used 
may explain this discrepancy. The choice for the DNA used in our ex-
periments related to our hypothesis that this would be the most similar 
to the cff-DNA found in the maternal circulation. Whole genomic fetal 
DNA used by Scharfe and colleagues has less biological relevance, as 
whole genomic DNA is not readily found in the circulation in that 
composition [46] moreover, cff-DNA is predominantly from placental 
origin and not from the fetus itself [2]. In addition, the demographics (e. 
g. gestational age) of the pregnant women from which PBMC were ob-
tained were not reported by Scharfe et al., and may be significant to 
outcomes. Gestational age and pregnancy complications can affect 
PBMC composition and the corresponding inflammatory response [47, 
48]. Furthermore, unlike the PBMCs from non-pregnant women, the 
effect of CpG on IL-6 production of the PBMCs from pregnant women 
was not reported [21]. To further analyse the response of DNA we also 
looked at the interferon-induced chemokine CXCL10, as 1 μg/ml of 
E. coli DNA can elicit a CXCL10 response from PBMCs [49]. Indeed, the 
CXCL10 response to cff-DNA is highly important in the context of 
placental inflammation, as CXCL10 is higher in the circulation of preg-
nant women with pre-eclampsia compared to uncomplicated pregnan-
cies [29] and that CXC chemokines are involved in the pathogenesis of 
pre-eclampsia [30]. However, primary placental explant cff-DNA was 
found not to induce CXCL10. 
The mechanisms that underpin the generation of cff-DNA in preg-
nancy remain to be determined, as does the contribution of placental 
inflammation, due to sterile inflammation or caused by infection, to this 
process [50,51]. LPS has been shown to increase apoptosis rates in 
placental trophoblasts [52] and mediate cff-DNA release from mouse 
placental explants [33]. In our placental explant model, using 
non-labouring term human placentas, we found that LPS-treated 
placental explants produced TNF-α in a concentration-dependent 
manner and significantly induced apoptosis by 24 h. However, we 
found no evidence that LPS-treated placental explants released higher 
amounts of cff-DNA compared to control samples. This suggests that 
LPS-induced inflammation and apoptosis alone may not be sufficient to 
cause a clinically relevant increases in cff-DNA. Indeed, pre-eclampsia is 
associated with significant amounts of placental necrosis, a cell death 
mechanism due to physical or chemical cell injury resulting in cell 
swelling and release of intracellular contents, compared to normal 
placentae [53]. Recently, pyroptosis, a form of cell death associated with 
inflammasome activation, has been found in decidual stromal cells from 
patients who developed preterm birth associated with inflammation and 
infection [54]. Future studies may therefore evaluate the role of necrosis 
Fig. 4. Primary human placental explant cff-DNA is not hypo-
methylatedDNA utilized was from E. Coli (E. coli DNA), genomic DNA from 
adult human blood leukocytes (Adult DNA), cff-DNA pooled from the blood of 
three pregnant women (clinical cff-DNA), genomic DNA extracted from primary 
placental explants (genomic placental DNA), or cff-DNA from placental ex-
plants, either untreated (control cff-DNA) or treated with 200 ng/ml LPS (LPS 
cff-DNA). Results are shown as percentage of total DNA CpG. Cff-DNA ¼ cell- 
free Fetal DNA, ND ¼ Not detected, values that were less than 0%. 
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and pyroptosis and their effect on cff-DNA release from placental 
explants. 
Using methylation restriction enzymes, human fetal DNA [21] and 
mouse placental DNA [23], have been shown to have hypomethylated 
DNA segments present, unlike adult DNA. This difference has been 
proposed as a key factor in their ability to elicit inflammation [24,55]. It 
is notoriously difficult to quantify the percentage of hypomethylated 
DNA present in a sample and methylation restriction enzymes require 
high levels of DNA (often not achievable from clinical cff-DNA samples) 
and are unable to quantify the amount of methylation is present in a 
sample [56]. We sought to quantify the percentage of hypomethylated 
DNA present in various samples and compare this to a confirmed TLR9 
ligand, E. coli DNA. We did this by using a method that can quantify the 
percentage of methylation present in a sample. However, the amount of 
methylation present in a sample does not represent the percentage of 
hypomethylation. Therefore, we quantified the amount of methylation 
present in our DNA after treatment with a methylation enzyme, used to 
methylate any hypomethylated sections of our DNA samples, and sub-
tracted this with the untreated DNA samples. This yields an indication of 
the amount of hypomethylation present in a DNA sample, but has a 
limitation that it cannot detect very small amounts of hypomethylation. 
This may explain the fact that many samples in our study had no 
hypomethylated DNA detected (see Fig. 4). Neverthles, in keeping with 
data from whole genome bisulfite sequencing, we demonstrate that 
cff-DNA, generated from placental explants and from pregnant women, 
does not differ in methylation from adult genomic DNA [57]. Impor-
tantly, we demonstrate that, when compared to E. coli DNA, there are 
very few hypomethylated segments present, and that LPS-induced 
inflammation does not alter the methylation status of cff-DNA, thereby 
not promoting its pro-inflammatory properties in that manner. Together 
with the data from our PBMC stimulations, it is plausible that this 
cff-DNA is not sufficiently hypomethylated to be pro-inflammatory, and 
to stimulate TLR9. 
In summary, cff-DNA is found in increasing amounts in the maternal 
circulation during pregnancy, but the regulation of this and the pro- 
inflammatory affects are not well understood. Based on our findings 
we propose that cff-DNA alone is not pro-inflammatory to PBMCs from 
pregnant women. This suggests that cff-DNA itself does not contribute to 
inflammation that can be seen in obstetric complications. Similarly, we 
show that the rise in cff-DNA measured in women with placental 
inflammation may not directly be caused by placental inflammation. 
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